Cofactor Biosynthetic Pathways in Mycobacterium tuberculosis as Potential Drug Targets

ISSN: 1875-6387 (Online)
ISSN: 1573-398X (Print)


Volume 10, 4 Issues, 2014


Download PDF Flyer




Current Respiratory Medicine Reviews

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Joseph Varon
The University of Texas Health Science Center
Houston, TX
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Cofactor Biosynthetic Pathways in Mycobacterium tuberculosis as Potential Drug Targets

Author(s): Shilpika Pandey, Sarthak Gaur, Neha Topno, Sidharth Chopra and Arunava Dasgupta

Affiliation: Division of Microbiology, CSIR-Central Drug Research Institute, B.S. 10/1, Sector 10, Janakipuram Extension, Sitapur Road, Lucknow - 226031, Uttar Pardesh, India.

Abstract

There are many chemotherapeutic interventions available for tuberculosis (TB) and are in use for more than five decades, but still there is an urgent need for novel drugs against new targets due to emergence of resistant strains. Moreover, the ability of Mycobacterium tuberculosis (Mtb) to survive within granulomas in a non-replicating latent stage prolongs the course of drug dose and hence increases the severity of the disease. The significant rerouting of metabolism is one of the key processes that help mycobacteria adapt to the hostile environment of host granuloma. In this review, we are focusing on some of the cofactor biosynthetic pathways of Mycobacterium tuberculosis and their utilization as drug targets.




Keywords: FAD, Mtb, NAD, Pantothenate, iron, vitamin.

Download Free Order Reprints Order Eprints Rights and Permissions

  
  



Article Details

Volume: 10
Issue Number: 2
First Page: 97
Last Page: 108
Page Count: 12
DOI: 10.2174/1573398X10666140822004506
Advertisement
Asthma & COPD:

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science